Fluidigm to Present at Upcoming Health Care Investor Conference
November 10, 2020 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Vystar Contracts Partners for Production of Rx3000 UV Light Air Purifiers that Inactivate Airborne Viruses
August 06, 2020 12:54 ET
|
Vystar Corp.
New manufacturer offers “Made in the USA” expanded production capacity, quality & fast deliveryRx3000® FDA certified Class II Medical device inactivates 99.97% of harmful airborne viruses &...
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
May 21, 2020 13:58 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
Fluidigm and Next Gen Diagnostics Enter into Agreement to Improve the Efficiency of Pathogen Sample Preparation for Microbial Whole Genome Sequencing
March 03, 2020 08:00 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif. and HINXTON, United Kingdom, March 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an industry leader in microfluidics technology, and Next Gen...
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
October 03, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile...
Summit Therapeutics to Host R&D Day 7 October 2019
September 25, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Host R&D Day 7 October 2019 Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc...
Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
September 24, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 Oxford, UK, and Cambridge, MA, US,...
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
February 07, 2019 09:18 ET
|
Vystar Corp
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria.Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other...
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
August 08, 2018 16:30 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
How to Treat Minor Cuts; American Academy of Dermatology
July 10, 2018 14:00 ET
|
American Academy of Dermatology
ROSEMONT, Ill., July 10, 2018 (GLOBE NEWSWIRE) -- Cuts from a sharp knife or a piece of glass are very common. They often occur while people are preparing food, washing dishes or even crafting. All...